Durable Long-Term Survival Following Autologous NK-Cell Consolidation in Multiple Myeloma: Phase I Data with Extended Follow-Up
- Sustained Long-Term Survival: Extended follow-up demonstrates significant overall survival benefit signal in ASCT eligible multiple myeloma cohorts
- Clinical Durability in High-Risk Populations: Notably, high-risk cytogenetic features by FISH achieved durable remission and long-term survival, suggesting potential broad therapeutic applicability across risk categories
- Advancement Toward Phase II & Beyond: Data support progression to a phase II trial aimed at confirming CR, PFS, and OS, expanding to multi-center sites, and exploring combination strategies to enhance NK-cell persistence and functional potency